Applied UV comments on CDC’s warning of C. auris spreading across facilities

Applied UV announces the Center of Disease Control, CDC, has warned that Candida auris, C. auris, is spreading rapidly through U.S. health care facilities. As the company previously announced, the Sterilumen family of disinfection devices was independently tested by ResInnova Laboratories who confirmed that the Company’s devices kill C.auris on sink handles, achieving a log2 kill in just fifteen minutes of operation. Applied UV’s recently acquired Puro UV completed independent lab testing commissioned by Violet Defense, the UV technology provider powering Puro’s Helo products, and performed at an EPA and FDA GLP-compliant, ISO 17025 Accredited Testing Laboratory. Testing determined that Puro UV disinfecting fixtures are effective at killing the C. auris fungus. Sterilumen’s complete family of air and surface disinfection devices including Airocide Air Purification System, a proprietary airborne pathogen killing technology originally developed for use by NASA and listed as a FDA Class II Medical Device that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst, kills the emerging multi-drug resistant fungus, Candida auris as well as its surface disinfection platform Lumicide. Additionally, independent research previously conducted demonstrated that Airocide also kills MRSA. Applied UV’s patented LumiCide Surface and Drain UVC Disinfecting Systems is currently installed within the world renowned Mt. Sinai Medical Center Morningside in a trial, the results of which are expected to be published late in Q3 2023 which would further validate the previously obtained independent results conducted by ResInnova Laboratories. This validation could facilitate the adoption of the Company’s LumiCide Surface and Drain disinfection solutions throughout healthcare facilities globally.